Raptiva, manufactured and distributed by Genetech Inc., is an injectible medication administered once a week to patients with psoriasis. Raptiva suppresses the immune system by blocking the activation of T-cells. Overactive T-cells can cause psoriasis. Raptiva has been linked to a variety of serious, often life-threatening, side effects, including cancer of the lymphatic system, meningitis, blood infections, and PML, which is a debilitating neurological disorder. These conditions, if left untreated, can be fatal.